PDCD1 and neoplasm: Despite considerable progress has been made in the treatment of cancers highly expressing PD‐L1, such as lung cancer, melanoma, and CRC, where some cancer patients have experienced substantial improvements in survival and some have even achieved complete remission, the tumor response rate to PD‐1/PD‐L1 antibody treatments remains inadequate.